论文部分内容阅读
目的比较替考拉宁与万古霉素对儿童耐甲氧西林金黄色葡萄球菌(MRSA)感染的临床疗效和副作用。方法对2010年7月至2013年4月本院收治MRSA肺炎患儿共95例进行分析,49例给予替考拉宁(前3 d 10 mg/kg,q12 h,然后10 mg/kg,qd),46例给予万古霉素(20 mg/kg,q12 h)治疗,两组均以14 d为一疗程,统计并比较两种方法的临床效果及副作用。结果结果显示,两组总有效率及两组间细菌清除率差异无统计学意义(P>0.05),但替考拉宁组在退热、止咳,白细胞及CRP恢复正常时间,住院时间上优于万古霉素组(P<0.01),副作用明显少于万古霉素组(P<0.01)。结论替考拉宁与稳可信治疗儿童MRSA肺炎的临床疗效临床疗效均较高,但替考拉宁安全性更好。
Objective To compare the clinical efficacy and side effects of teicoplanin with vancomycin in children with methicillin-resistant Staphylococcus aureus (MRSA) infection. Methods A total of 95 patients with MRSA pneumonia admitted to our hospital from July 2010 to April 2013 were analyzed. 49 patients were given teicoplanin (qd, 10 mg / kg, qd ), And 46 cases were given vancomycin (20 mg / kg, q12 h). Both groups were treated for 14 days. The clinical effects and side effects of the two methods were compared and compared. The results showed that there was no significant difference in total effective rate and bacterial clearance rate between the two groups (P> 0.05), but the teicoplanin group was superior in fever, cough, white blood cells and CRP recovery time, In vancomycin group (P <0.01), side effects were significantly less than those in vancomycin group (P <0.01). Conclusion The clinical curative effect of teicoplanin and stable cretinism in children with MRSA pneumonia is high, but teicoplanin is more safe.